News
TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months
The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology.
ACR 2020 Your Way - Get Your Topic Emails
ACR is but a few days away; the question is: how will you tackle this virtual meeting? RheumNow has created several options for learning the way you want to. First is to feed your need. Are you a lupologist? A gout maven? A Spondylitis sleuth? A drug safety wannabe?
Long-Term Benefits of Ixekizumab in Psoriatic Arthritis
The SPIRIT-P1 study has demonstrated the safety and efficacy of ixekizumab (an IL-17A antagonist) when given to adults w/ active psoriatic arthritis (PsA), and also demonstrating radiographic protection and improvement in skin outcomes as well.
SPARTAN ACR20 Recommendations on Spondyloarthritis
SPARTAN has compiled a list of presentations and sessions worth seeing if you are interested in ankylosing spondylitis, spondyloarthritis and related disorders.
US Differs from Worldwide Drug Reimbursements
"The US has nearly 4.5% of the world’s population but accounts for more than 40% of global drug spending" reports JAMA Internal Medicine. US drug prices are nearly double those of Australia, Canada, and the United Kingdom, and the US spends twice as much on retail and nonretai
Are Rheums Attending ACR 2020?
ACR 2020 (aka ACR Convergence) is just around the corner, with the opening ceremonies and lecture starting Thursday, November 5th; followed by the full meeting beginning the next morning, Friday November 6th.
RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)
Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com
Abatacept in Early Systemic Sclerosis (ASSET study)
An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).
FDA Invites Patient Input on Systemic Sclerosis Drug Development
While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.
Guselkumab, an IL-23 Inhibitor, Effective in Psoriatic Arthritis
The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.
